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Introduction: Despite recent advances in treatment, lung cancer
remains the leading cause of cancer-related mortality in the United
States. Therefore, there is a strong need for developing clinical trials
in lung cancer therapeutics. Only a small fraction of patients with
lung cancer are enrolled in clinical trials. It is critical to understand
the barriers to participation in lung cancer clinical trials.
Methods:We reviewed the outpatient charts of consecutive patients
with non-small cell lung cancer who presented for initial evaluation
or consultation for further therapeutic management to the thoracic
medical oncology group at the Alvin J. Siteman Cancer Center
between January 1, 2006, and December 31, 2006. Available and
appropriate clinical trials specific to the histologic subtype and stage
were presented to the patients routinely, and reasons for nonenroll-
ment were documented. We collected information on age, gender,
ethnicity, histology, stage, performance status (PS), and insurance
status.
Results: During the study period, 263 patients with non-small cell
lung cancer were identified for the study. After initial screening, 183
patients had clinical trials available, which were appropriate for their
diagnosis and stage of disease. One hundred one patients (55.2%)
were ineligible for enrollment in a clinical trial. The most common
reasons for ineligibility were poor PS (18%), need for emergent
radiation (12%), lack of adequate staging information (6%), and
comorbid conditions (4.9%). Despite being eligible for participation,
57 patients (31.1%) did not enroll in a clinical trial. Patient refusal
accounted for 8.7%. The problems with transportation and distance
from the medical center were reasons given for nonparticipation by
7.1%. Eleven patients (6%) did not participate in a clinical trial
because of insurance issues. Ultimately, 25 patients (13.7%) were
enrolled in a clinical trial.
Conclusions: Poor PS, the need for emergent radiation, and patient
refusal were the most common reasons for not participating in a
clinical trial.
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The American Cancer Society estimates 159,390 lung can-cer-related deaths in 2009.1 Non-small cell lung cancer
(NSCLC) accounts for approximately 87% of lung cancer
cases.2 Approximately 70% of patients diagnosed with lung
cancer have stage III or IV disease at the time of presenta-
tion.3 With the introduction of novel agents for systemic
therapy, we have seen a modest improvement in overall
survival of patients with NSCLC.4 Adult patients with cancer
are seldom enrolled in clinical trials.5–7
The barriers to enrollment of patients with cancer in
clinical trials include administrative factors such as lack of
availability of appropriate clinical trials and delays in opening
trials; physician factors such as bias against clinical trials and
lack of support of staff and infrastructure; and finally patient-
related factors, which include patient bias against clinical
trials, poor performance status (PS), comorbidities, insurance,
and transportation issues.5,8
Accrual rates for cancer clinical trials are low even in
established comprehensive cancer centers in the United
States. Identifying factors limiting enrollment in lung cancer
therapeutic clinical trials is crucial in designing trials geared
to focus on problem areas. Therefore, we performed this
study to specifically evaluate the barriers to enrollment in
NSCLC clinical trials in a tertiary care center.
MATERIALS AND METHODS
We reviewed the charts of consecutive outpatients with
NSCLC who presented for initial evaluation or consultation
for further therapeutic management to the thoracic medical
oncology group at the Alvin J. Siteman Cancer Center (SCC)
between January 1, 2006, and December 31, 2006.
The SCC is a National Cancer Institute-designated
Comprehensive Cancer Center at Washington University
School of Medicine in St. Louis, Missouri. SCC is a member
of the Cancer and Leukemia Group B (CALGB), Radiation
Treatment Oncology Group, and American College of Sur-
gical Oncology. SCC has two satellite locations in the com-
munity. The SCC thoracic medical oncology group consists
of five medical oncologists and their staff. As a part of the
thoracic oncology service, there are five thoracic surgeons
and two radiation oncologists. The SCC clinical trial office
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has a large staff, with one regulatory manager and three
research associates solely dedicated to the thoracic group.
Available and appropriate clinical trials are presented to
the patients routinely, and reasons for nonenrollment are
documented. We collected information on histology, stage,
PS, and comorbid conditions. Appropriate studies at the time
of initial consultation were noted from the SCC database
based on the histologic subtype and staging before a formal
individualized eligibility review was conducted.
The data analysis for this study was descriptive in
nature. The distribution for continuous variables such as age
was described using medians and ranges, whereas the cate-
gorical features were summarized with counts and frequen-
cies. The patient characteristics across groups by enrollment
status were compared using Kruskall-Wallis rank sum test or
Fisher’s exact test as appropriate.
RESULTS
During the study period, 263 patients with NSCLC
were seen for initial consultation by the thoracic medical
oncology group at the SCC. During the time frame of this
study, there were 29 therapeutic clinical trials open, which
included 4 phase I/II trials, 22 phase II trials, and 3 phase III
trials. Ten patients did not require treatment, and 26 patients
had already initiated therapy and were not considered for
participation in a therapeutic clinical trial in lung cancer. In
addition, 44 patients did not have an appropriate clinical trial
at the time of consultation. After initial screening, 183 pa-
tients had clinical trials available, which were appropriate for
their histologic diagnosis and stage of disease before per-
forming a comprehensive eligibility check. Figure 1 illus-
trates the process by which we identified these 183 patients.
Table 1 shows the clinical characteristics of the 183 patients
(94 men, 51.4%) with clinical trials available appropriate for
their diagnosis and stage of disease. The median age of the
group was 63 years (range 18–100 years). Consistent with
local demographics, majority of patients were whites (70.5%)
followed by African Americans (21.9%). The most common
histologic subtype seen was adenocarcinoma (43.7%), fol-
lowed by NSCLC-not otherwise specified (40.4%), squamous
cell (13.1%), bronchioloalveolar (1.1%), large cell (0.5%),
and other subtypes (1.1%). Most of the patients seen had
stage IV (64.5%) or stage III (27.3%) disease. The majority
of our patients carried private insurance (60.7%), whereas
others had Medicare (18.6%), Medicaid (14.2%), or no in-
surance (6.6%).
Of the 183 patients for whom appropriate clinical
trials were available (based on the histologic diagnosis and
staging), 101 patients (55.2%) did not meet clinical trial
eligibility when individualized review was conducted. De-
spite being eligible for trials, 57 patients (31.1%) were not
enrolled in a clinical trial. Only 25 patients (13.7%) were
ultimately enrolled in therapeutic clinical trials. Three
patients enrolled in phase I/II trials, and the remaining 22
enrolled in phase III trials
The reasons for not participating in a lung cancer
therapeutic clinical trial are listed in Table 2. For consistency,
we used 183 as the denominator for all calculated percentages
in this table. As mentioned earlier, ineligibility for clinical
trial participation was a major barrier. Reasons for ineligibil-
ity included poor PS (18%), need for emergent radiation
(12%), lack of adequate staging information (6%), comorbid
conditions (4.9%), presence of brain metastases (3.8%), sec-
ond malignancy (3.3%), heavily pretreated patients (2.2%),
contraindication to study drug (1.6%), mixed histology
(1.1%), absence of measurable disease (1.1%), and other
(1.1%). The last category included a patient with elevated
liver enzymes and creatinine and another patient with too
large radiation field to go on study.
Despite being eligible for participation, 57 patients did
not enroll in a clinical trial. Patient refusal (no specific
explanation provided) accounted for 8.7%. The problems
with transportation and the distance from the medical center
were given as reasons for nonparticipation by 7.1%. Eleven
patients (6%) did not participate in a clinical trial because of
insurance issues. Three patients (1.6%) were lost to follow-
up, two patients (1.1%) had issues with compliance to ther-
apy, and data were not available for two patients (1.1%).
FIGURE 1. Flow diagram of patients enrolled on a clinical
trial.
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Table 3 compares the characteristics of the following
three groups: those who enrolled in a trial, patients who were
eligible for trial participation but did not enroll in a trial, and
patients who did not meet eligibility criteria for participation
in a clinical trial although a trial was available for their
histologic diagnosis and stage of disease. We did not find any
significant differences in the any categories examined includ-
ing gender, age, ethnicity, histology, stage, or insurance
status perhaps likely to the small sample size.
DISCUSSION
Poor enrollment in clinical trials continues to be vexing
problem in oncology today. The enrollment rate of 13.7%
reported here is similar to what has been reported in the
literature.7 Careful analyses of the factors limiting enrollment
in clinical trials are necessary to make significant progress in
the treatment of cancer. Even though trials are often available
for patient with almost any stage of NSCLC, several factors
influence eventual enrollment. Poor PS is a common problem
in patients with NSCLC and is an adverse prognostic factor
irrespective of stage.9 Most clinical trials are designed for
patient with a PS of 0 to 1, even in the second-line setting.
Clinical and translational studies need to be conducted with
even more vigor in this population of patients with NSCLC.
Persistent and continuing low accrual rates hinder
progress in this field by prolonging the duration of trials,
leading to premature closure of studies from poor accrual and
generating insufficient data to analyze. For instance, 9.4% of
CALGB protocols failed to meet accrual goals over a 9-year
period (1989–1997), and 20% of current CALGB protocols
are lagging behind expected accruals.10 This poses consider-
able strain on as system already burdened with administrative
issues as reported by Dilts and Sandler,11 who described half
of the process steps required to open a trial to be nonvalue
added steps. Clearly, the process of opening trials needs to be
streamlined, and efforts need to be made to improve enroll-
ment on clinical trials.
Lack of adequate reimbursement and infrastructure,
time constraints, and their own misconception of patients’
attitudes about research could dampen physicians’ enthusi-
asm to promote participation in clinical trials. Fenton et al.
analyzed data from a US national online survey conducted
among 200 patients with lung cancer, 206 patients with other
cancers, and 200 oncologists to compare their perception
regarding clinical trials. Almost half of the oncologists sur-
veyed reported that patients’ fear of side effects and being
assigned to the placebo arm were two critical factors limiting
participation in lung cancer clinical trials. However, when the
authors surveyed a group of 200 patients with lung cancer,
TABLE 1. Patient Characteristics (n  183)
Patients with Clinical
Trial Available
Patients with Clinical
Trial Available (%)
Gender
Male 94 51.4
Female 89 48.6
Age (yr)
Median 63
Range 18–100
Race/ethnicity
White 129 70.5
African American 40 21.9
Other 4 2.2
Unknown 10 5.5
Histology
Adenocarcinoma 80 43.7
NSCLC0020NOS 74 40.4
Squamous 24 13.1
Bronchioloalveolar 2 1.1
Large cell 1 0.5
Other 2 1.1
Stage
IA 4 2.2
IB 4 2.2
IIA 1 0.5
IIB 3 1.6
IIIA 22 12.0
IIIB 28 15.3
IV 118 64.5
Unknown 3 1.6
Insurance status
Private 111 60.7
Medicare 34 18.6
Medicaid 26 14.2
Self-pay 12 6.6
NSCLC, non-small cell lung cancer; NOS, not otherwise specified.
TABLE 2. Reasons for Nonparticipation in Clinical Trial
Clinical Trial Enrollment Status
No. of
Patients
Patients with
Clinical Trials
Available (n  183)
Ineligibility for clinical trial 101 55.2
Poor performance status 33 18.0
Emergent radiation 22 12.0
Staging incomplete 11 6.0
Comorbid conditions 9 4.9
Brain metastasis 7 3.8
Second malignancy 6 3.3
Heavily pretreated 4 2.2
Contraindication to study drug 3 1.6
Mixed histology 2 1.1
No measurable disease 2 1.1
Other 2 1.1
Eligible for clinical trial,
but did not enroll
57 31.1
Patient refusal 16 8.7
Travel distance 13 7.1
Insurance issues 11 6.0
Lost to follow-up 3 1.6
Compliance issues 2 1.1
Note unclear 2 1.1
Other 10 5.5
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only a minority reported fear of placebo (8%) or side effects
(10%) as their major concerns.7
Reasons for patient refusal to participate in a clinical trial
have been studied in patients with lung cancer. The most
commonly cited ones are the difficulties associated with a
randomized study design and the personal desire to be actively
involved in decision making, and distrust of the medical
profession with the refusal to see one self as an experimental
subject, insurance denial, and distance from clinic.5,12,13
Transportation was a barrier to clinical trial participation in
our study. To assist patients traveling long distances for
consultation, most large centers, including SCC, have free
lodging arrangements for patients and their families. Al-
though it may be possible for patients to make a single trip for
second opinion regarding therapy or to be intermittently seen
while being primarily managed by a local oncologist, re-
peated trips for the purpose of receiving investigational ther-
apy or participating in a clinical trial may not be feasible.
This supports the role of the Community Clinical Oncology
Program in connecting large academic centers, which design
and open clinical trials, to community physicians who accrue
patients to these trials.
National Institutes of Health stipulates inclusion of
minority groups in clinical trials.14 However, representation
of racial and ethnic minorities in clinical trials has remained
low.15,16 Bolen et al.14 constructed a framework for choosing
a priori recruitment goals for underrepresented groups in an
effort to increase their representation in clinical trials. How-
ever, it is possible that underrepresentation of minorities,
such as African American patients in cancer clinical trials
may be confounded by other variables, such as education and
socioeconomic status, as Advani et al.17 found in a pilot
study. Interventions that target community outreach, re-
search, and education in this group may translate into im-
proved recruitment in clinical trials. Program for the Elimi-
nation of Cancer Disparities was established in October
2003 to address one of the SCC’s top priorities: reducing
cancer disparities in our community. Program for the
Elimination of Cancer Disparities coordinates SCC activ-
ities that enhance underserved patients’ access to quality
clinical care and research studies, including educational
activities, cancer prevention, screening, treatment, pallia-
tive care, and family support.
Insurance issues were also a significant barrier to en-
rollment in clinical trial at our institution. There is a percep-
tion that patients enrolled in clinical trials incur additional
costs compared with patients receiving standard of care
therapy.18 This leads to private insurance plans frequently
denying reimbursement for patient care as a part of a clinical
trial. However, studies looking at incremental treatment costs
for patients on cancer clinical trials have found modest cost
differences of 0 to 10%.19 More work needs to be done with
insurance companies to ensure that standard of care treatment
is covered for patients enrolled in clinical trials. Study-
associated costs could be further reduced by simplifying
enrollment criteria and eliminating unnecessary repetitive
testing before, during, and after treatment. Data collection
can also be simplified, so that only data pertaining to serious
adverse events are collected.
With the increasing availability of several agents for
NSCLC, there is an urgent need to develop innovative strat-
egies to improve clinical trial accrual. It is difficult to make
meaningful progress in the treatment of NSCLC without
overhauling the clinical trial process. This can only be
achieved by developing appropriate clinical trials for specific
subpopulations (clinically and molecularly defined), educat-
ing patients and physicians about the implications of re-
search, and most importantly easing the cumbersome admin-
istrative burdens currently associated with clinical trials.
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